Related Experiment Video
Updated: Aug 20, 2026

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
Published on: April 3, 2026
Tegafur-Uracil (UFUR) as Maintenance Therapy in Resectable and Unresectable Head and Neck Squamous Cell Carcinoma: A
Hui-Ching Wang1,2, Pen-Yuan Chu3,4
1Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Abstract:
Head and neck squamous cell carcinoma (HNSCC) remains associated with high rates of locoregional recurrence and distant metastasis despite definitive treatment. Metronomic tegafur-uracil (UFUR), an oral fluoropyrimidine comprising tegafur and uracil, has emerged as a potential maintenance strategy because of its cytotoxic, immunomodulatory, and anti-angiogenic mechanisms mediated by 5-fluorouracil (5-FU) and gamma-hydroxybutyric acid (GHB). This narrative review summarizes current evidence on UFUR maintenance in both resectable and unresectable HNSCC. Most available evidence is derived from retrospective and observational studies using maintenance durations ranging from approximately 6 months to 2 years. A recent meta-analysis of six observational studies (n = 1373) reported pooled hazard ratios of 0.68 for progression-free survival and 0.54 for overall survival; however, trial sequential analysis supported sufficient evidence only for progression-free survival, whereas the overall-survival evidence remained inconclusive. Published cohorts suggest potential benefits in selected high-risk patients and a generally manageable toxicity profile, but their findings remain susceptible to selection bias, residual confounding, and immortal-time bias. Prospective randomized trials are needed to confirm clinical benefit and define optimal treatment duration, patient selection, and potential integration with contemporary immunotherapy.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Tumor Immunotherapy
